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Abstract
Background: The WHO has recommended the implementation of rapid diagnostic tests to detect and help combat M/XDR
tuberculosis (TB). There are limited data on the performance and impact of these tests in field settings.
Methods: The performance of the commercially available Genotype MTBDRplus molecular assay was compared to
conventional methods including AFB smear, culture and drug susceptibility testing (DST) using both an absolute
concentration method on Lo ¨wenstein-Jensen media and broth-based method using the MGIT 960 system. Sputum
specimens were obtained from TB suspects in the country of Georgia who received care through the National TB Program.
Results: Among 500 AFB smear-positive sputum specimens, 458 (91.6%) had both a positive sputum culture for
Mycobacterium tuberculosis and a valid MTBDRplus assay result. The MTBDRplus assay detected isoniazid (INH) resistance
directly from the sputum specimen in 159 (89.8%) of 177 specimens and MDR-TB in 109 (95.6%) of 114 specimens compared
to conventional methods. There was high agreement between the MTBDRplus assay and conventional DST results in
detecting MDR-TB (kappa=0.95, p,0.01). The most prevalent INH resistance mutation was S315T (78%) in the katG codon
and the most common rifampicin resistance mutation was S531L (68%) in the rpoB codon. Among 13 specimens from TB
suspects with negative sputum cultures, 7 had a positive MTBDRplus assay (3 with MDR-TB). The time to detection of MDR-
TB was significantly less using the MTBDRplus assay (4.2 days) compared to the use of standard phenotypic tests (67.3 days
with solid media and 21.6 days with broth-based media).
Conclusions: Compared to conventional methods, the MTBDRplus assay had high accuracy and significantly reduced time
to detection of MDR-TB in an area with high MDR-TB prevalence. The use of rapid molecular diagnostic tests for TB and drug
resistance should increase the proportion of patients promptly placed on appropriate therapy.
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Introduction
The global emergence of multidrug-resistant (MDR) tubercu-
losis (resistance to isoniazid [INH] and rifampicin [RIF]) is an
alarming issue in international tuberculosis (TB) control and
presents an enormous challenge not yet sufficiently addressed [1].
The latest global surveillance data indicate the highest level of
drug-resistance ever recorded with an estimated 440,000 MDR-
TB cases worldwide resulting in 150,000 deaths in 2009 [2].
MDR-TB has proven difficult to treat due to costly, complex, and
less effective treatment regimens and is associated with signifi-
cantly worse outcomes as compared to drug susceptible disease
[3]. Of particular concern is that only an estimated 7% of all
MDR-TB cases are detected [2]. Conventional AFB culture and
drug susceptibility testing (DST) requires significant laboratory
infrastructure and has a slow turnaround time which can result in
delayed initiation of proper therapy and increasing risk of disease
transmission and amplification of drug resistance due to initiation
of inadequate treatment regimens [4]. In response to the growing
problem of MDR-TB, the STOP TB strategy has made universal
access to diagnosis and treatment of MDR-TB a priority with a
focus on rapid MDR-TB detection [5].
Responding to the urgent need for rapid diagnostic tests, several
molecular based methods have been developed in the last few
years including the commercially available line probe assay, the
Genotype MTBDRplus assay [Hain Lifescience] [6]. The
Genotype MTBDRplus assay uses DNA amplification followed
by reverse hybridization to detect the presence of M. tuberculosis
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resistance to RIF (in rpoB gene) and INH (in katG and inhA genes).
Trained personnel can perform the test within 8 hours. A recent
meta-analysis found the Genotype MTBDRplus assay performed
well, as compared to conventional DST [7]. Based on available
data and expert opinion the WHO has approved the use of line
probe assays (LPA) for rapid MDR-TB screening; specifically
recommending testing in patients with acid-fast bacilli (AFB)
positive smears and the use of commercial LPAs [8]. While tests
such as the Genotype MTBDRplus assay offer great promise to
improving MDR-TB detection and care, the urgent need for
operational research evaluating test performance in a real-world
setting has been highlighted [9].
Georgia (a former Soviet republic) is one of twenty-seven high
burden MDR-TB countries as designated by the WHO [2]. In
2009, the TB incidence rate in Georgia was 100 per 100,000. The
prevalence of MDR in Georgia in 2009 was 10.3% in newly
diagnosed patients and 31.1% in previously treated patients [10].
With the support of the Global Fund and the Green Light
Committee (GLC), Georgia has became one of the first low and
middle income countries to achieve universal access to diagnosis
and treatment of MDR-TB beginning in 2008. The primary
objective of our study was to assess the performance, impact, and
time to detection of drug resistant TB of a rapid molecular
diagnostic test compared to conventional culture and DST
methods when implemented into the normal workflow of a high
volume National TB Reference Laboratory (NRL) which provides
laboratory support for the Georgian National TB Program (NTP).
Methods
Study Setting and Population
The study took place at the NRL of the Georgian NTP in
Tbilisi, Georgia. The NRL processes specimens for the entire
country of Georgia. Approximately 15,000 sputum specimens
were processed at the NRL in 2010.
Between June and October 2009, all AFB smear positive
sputum specimens obtained from TB suspects without previous
history of TB from throughout Georgia were consecutively
enrolled into the study. Subsequently, from February through
July 2010, all TB cases with AFB smear positive sputum specimens
(regardless of prior treatment status) from Tbilisi, Georgia were
consecutively enrolled into the study. All testing was performed on
routine clinical sputum specimens.
Ethics Statement
The study was conducted according to the principles of the
Declaration of Helsinki. The Georgian NTP and Emory
University Institutional Review Boards approved the study and
granted a waiver of informed consent for the study. All samples
were de-identified of personal identifiers for data entry and data
analysis.
Culture and Drug Susceptibility Testing (DST)
Three sputum specimens were obtained from each patient at
NTP sputum microscopy centers throughout the country. Direct
smears with Ziehl-Neelsen staining were examined by light
microscopy at local microscopy centers. One AFB smear positive
sputum sample was sent to NRL in Tbilisi where it was processed
using standard methodologies (decontaminated in a BSL3 area
with N-acetyl-L-cysteine-sodium hydroxide, centrifuged, and the
sediment was then suspended in 1.5 ml of phosphate buffer) [11].
The processed specimen was inoculated on to both Lo ¨wenstein-
Jensen (LJ) based solid medium and the BACTEC MGIT 960
broth culture system. The duration of incubation for LJ solid
culture was 60 days and for MGIT broth culture 42 days. Positive
cultures by either method were confirmed to be Mycobacterium
tuberculosis complex (MTBC) using the MTBDRplus assay along
with colony morphology [6]. DST for INH and RIF was
performed using either the absolute concentration method on LJ
medium (INH 0.2 mg/ml, RIF 40 mg/ml) or in 7H9 broth with the
BACTECT MGIT 960 system (INH 0.1 mg/ml, RIF 1 mg/ml)
[12]. DST to second-line drugs (SLDs) was performed using the
proportion method on LJ medium with the following drug
concentrations: ethionamide-40.0 mg/ml; ofloxacin-2.0 mg/ml;
para-aminosalicylic acid-0.5 mg/ml, capreomycin-40.0 mg/ml
and KM-30.0 mg/ml [13]. The NRL has undergone external
quality assessment by the Antwerp WHO Supranational TB
Reference Laboratory annually since 2005. The last round of
quality control for first-line drugs was performed in 2009 with 97%
accuracy for INH and 100% for RIF.
Genotype MTBDRplus Assay
The MTBDRplus assay was performed directly on sputum samples
and according to the manufacturer’s instructions [6]. A portion of the
same sputum specimen was used for both molecular testing and
culture at the NRL.A 500-ml portion of decontaminated samples was
used for DNA isolation; subsequent amplification and hybridization
was based on manufacturers recommendations [6]. Each step was
carried out in a separate room with unidirectional workflow between
rooms. After hybridization, test strips were allowed to dry before
attached to paper. Each strip consists of 27 reaction zones (bands)
including controls that were interpreted according to manufacturers
instructions to determine test validity, MTBC identification, and
resistance to INH and RIF. An internal quality control program with
positive and negative controls was implemented during the study.
The MTBDRplus assay was performed two to three times per week
with between 2–8 samples used per run.
Definitions
INH mono-resistance was defined as M. tuberculosis resistance to
INH without resistance to RIF. RIF mono-resistance was defined
as resistance to RIF without resistance to INH. MDR-TB was
defined as resistance to both INH and RIF. New cases were
defined as patients who had received #30 days of TB treatment
and retreatment cases as all patients with a prior history of
receiving TB treatment for .30 days. A completely interpretable
MTBDRplus result was defined as a test strip with all control
markers positive.
Data Analysis
All data were entered into an online REDCap database [14]
and analyzed using SAS 9.3 (SAS Institute Inc., Cary, NC). The
sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) of the MTBDRplus assay in detecting
resistance to INH, RIF, and MDR were calculated using
conventional culture and DST results as the reference standard.
Turnaround time was calculated as time between the date of
sputum collection and date of culture, DST, and MTBDRplus test
results. The degree of agreement between test results were assessed
using the kappa (k) statistic with a value of k=1 denoting perfect
concordance, and k=0 denotes agreement by chance alone. A p-
value of ,0.05 was considered statistically significant.
Results
A total of 500 patients with suspected pulmonary TB who had a
smear positive AFB sputum specimen were enrolled into the study.
Rapid Diagnostic Testing for Tuberculosis
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and 121 (24%) were retreatment TB cases. Overall, 474 (95%)
samples were culture positive by either conventional method (92%
had positive liquid culture, and 79% positive solid culture), 2.6%
were culture negative, and 2.6% had contaminated cultures
(Figure 1). All culture negative cases had 1+ AFB smear positivity.
DST of M. tuberculosis was performed in liquid media in 325
(69%) or solid media in 149 (31%). Conventional DST revealed
114 (25%) M. tuberculosis (MTB) isolates had multidrug resistance,
63 (14%) were isoniazid mono-resistance, and 2 (0.4%) isolates
were rifampin mono-resistant (Figure 2). There was a much higher
rate of MDR TB among patients with a prior history of TB
treatment as compared to persons never treated for TB (54% vs.
16%, p,0.05). Second line drug susceptibility testing of MDR
isolates revealed 11(10% of MDR cases and 2% of all culture
positive cases) had XDR. Of the 11 XDR cases 4 of 47 were new
TB cases and 7 of 51 were retreatment TB cases.
MTBDRplus Assay Performance
The MTBDRplus assay identified the presence of M. tuberculosis
in 485 (97%) of 500 sputum samples and had completely
interpretable results in 475 (95%). Overall, there was no significant
difference in the proportion of interpretable results between
conventional methods and the MTBDRplus assay (97% vs. 97%,
p=0.90). Among 474 sputum samples which subsequently yielded
a positive culture for M. tuberculosis, 458 (97%) had a completely
interpretable MTBDRplus assay. Of the 16 results with positive
culture and incomplete MTBDRplus assay results, the
MTBDRplus assay identified MTBC in 10 but did not have
complete amplification of the RIF and/or INH bands, and in 6
samples had control amplification but did not identify the presence
of M. tuberculosis DNA, indicating the presence of a non-
tuberculous Mycobacterium. Figure 2 shows MTBDRplus results
for four different categories of results of drug resistance testing as
detected by conventional DST. Performance parameters of the
MTBDRplus assay as compared to conventional DST for
detection of RIF, INH, and MDR are displayed in Table 1.
The overall sensitivity, specificity, positive predictive value, and
negative predictive value of the MTBDRplus assay in the detection
of RIF resistance, INH resistance, and MDR were high (Table 1).
The sensitivity of the MTBDRplus assay in detection of INH
resistance among isolates with INH mono-resistance was less than
the detection of INH resistance in MDR-TB isolates (73% vs.
99%, p,0.05). There was high agreement between the
MTBDRplus assay and conventional DST in detection of RIF
resistance (k=0.94; 95% CI 0.91–0.98), INH resistance (k=0.91;
95% CI 0.87–0.95), and MDR (k=0.95; 95% CI 0.92–0.99). The
performance of the MTBDRplus assay was similar in cases with or
without prior treatment for TB except decreased sensitivity of INH
resistance detection in persons without prior treatment for TB as
compared to persons with prior TB treatment (86.0% vs. 95.7%,
p,0.05).
The MTBDRplus assay gave interpretable results for the
majority (17 of 26, 65%) of specimens with negative or
contaminated sputum cultures (Figure 1). In 13 sputum samples
from patients suspected of having pulmonary TB but in whom the
sputum culture had no growth, the MTBDRplus assay identified
M. tuberculosis in 7 (54%) specimens including 3 specimens in which
multidrug resistance was identified by the MTBDRplus assay. In
the 13 specimens with contaminated cultures, the MTBDRplus
assay identified MTBC complex in 10 (77%) specimens of which 2
were MDR-TB.
Time to Results
Time to detection of M. tuberculosis and drug resistance were
significantly shorter for the MTBDRplus assay compared to
conventional methods using solid and liquid culture and DST
(Table 2). On average, a MTBDRplus test result for the detection
of M. tuberculosis was available by 4.2 days (1SD+/21.8 days) while
positive solid culture and liquid culture results were not available
until 34.1 (1SD+/211.3 days) and 8.9 days (1SD+/23.9 days),
respectively. In regards to drug resistance, the MTBDRplus result
for detection for INH and/or RIF resistance was available by 4.2
days (1SD+/21.8 days) as compared to solid and liquid media
DST results which were not available until 67.5 (1SD+/215.0)
and 21.6 days (1SD+/29.3 days), respectively. The time to
detection of drug resistance was similar for MDR or mono-
resistant specimens.
Genetic Mutations
The distribution of genetic mutations of drug-resistant M.
tuberculosis isolates with an interpretable MTBDRplus assay
(n=179) is shown in Table 3. The most common resistance
mutation for INH was S315T (78%) in the katG codon followed by
C15T (28%) in the inhA codon. Additionally, a high percentage of
isolates (72%) had no binding to the katG WT probe. Overall, 18
(10%) of 177 INH resistant isolates had a genetic abnormality
isolated to the InhA codon; but this mutation was significantly more
common in INH mono-resistant isolates compared to strains with
Figure 1. Sputum culture results for all AFB smear positive tuberculosis suspects and corresponding complete MTBDRplus assay
results.
doi:10.1371/journal.pone.0031563.g001
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INH mono-resistant isolates, MDR isolates had an increased
frequency of the S315T mutation (92% vs. 52%, p,0.05) and less
binding to the katG WT probe (10% vs. 54%, p,0.05). Isolates
from persons with prior TB treatment were more likely to have
either a genetic mutation in the katG codon or lack of binding to
katG WT probe (95.5% vs. 83.4%, p,0.05) and an increased
likelihood of having a genetic mutation or lack of binding to WT
gene region in both katG and inhA codons (23.9%. vs. 17.2%,
p=0.29). In RIF resistant isolates, the most common genetic
abnormality was the lack of binding to the WT8 probe in 80%,
followed by the S531L mutation in 68%. Of the five isolates with
RIF resistance by the MTBDRplus assay but RIF S by
conventional DST all five were RIF resistance due to the lack of
binding to one or more WT bands with no mutation bands
present.
Predicting Ethionamide Resistance
Among 109 MDR-TB isolates with DST performed for second
line drugs, 102 (94%) were found to be resistant to ethionamide.
While the sensitivity and negative predictive value of any
abnormality in the inhA gene in detecting ethionamide resistance
were low at 29% and 9% respectively, the specificity and positive
predictive value were both 100%.
Discussion
In a high-burdened MDR-TB country, the MTBDRplus assay
performed extremely well in the detection of M. tuberculosis
complex and MDR-TB as compared to conventional culture
and DST. This rapid molecular diagnostic test can be performed
directly on sputum samples from patients with suspected
pulmonary TB and demonstrated a high accuracy in our study
detecting M. tuberculosis and for detecting INH and RIF resistance
compared to conventional culture and DST methodologies. In
addition, the MTBDRplus detected drug resistance much more
quickly than conventional methods (3.7 days with MTBDRplus
assay vs. 21.1 days with liquid media DST vs. 70.4 with solid
media DST); a finding which has great implications in improving
the clinical care of MDR-TB patients. The results demonstrate
line probe assays can be successfully implemented into the routine
workflow of a high volume national reference laboratory.
The high sensitivity (95.6%), specificity (98.5%), PPV (95.6%),
and NPV (98.5%) in the detection of MDR-TB in our study
correlate well with findings from a previous report evaluating the
MTBDRplus assay in South Africa [15]. While other studies
assessing the MTBDRplus assay found high test accuracy, most
were performed on stored samples and in a purely research setting
[16,17,18], thus limiting the generalizability of the results for
routine clinical practice. Additionally, we found that the
MTBDRplus gave valid results in majority of cases where there
was culture contamination (77%) or no culture growth (54%)
demonstrating the MTBDRplus test may offer superior perfor-
mance to conventional methods. Five MDR-TB cases were
detected by the MTBDRplus test only; otherwise these cases
would have gone undetected due to no culture growth (n=3) or
contamination (n=2). Similarly, there were five cases found to
MDR by conventional DST but only INH (n=4) or RIF (n=1)
mono resistance by the MTBDRplus assay. It has been speculated
that samples with a valid MTBDRplus test result but no growth on
culture may be the result of excess decontamination, which can kill
a high percentage of mycobacteria in a specimen [19].
While the sensitivity of the molecular diagnostic test for
detection of INH resistance in our study was slightly lower than
that for RIF and MDR detection (compared to conventional
methods), it was in line with prior studies [7]. The slightly lower
sensitivity of the MTBDRplus test for INH compared to
conventional methods is likely due to genetic mutations conferring
INH resistance that are located outside the katG and inhA genes
[20]. Almost all missed cases (17 of 18, 94%) of INH resistance
with genotypic testing were in INH mono-resistant cases, a finding
found in a prior study [16]. Thus clinical consequences may be
mitigated, as initial treatment regimens for INH mono-resistance
incorporate standard first line therapy and outcomes of INH
mono-resistance TB have been found to be similar to drug
susceptible TB [21]. We found the most common genetic
mutations conferring INH resistance were located in the katG
Figure 2. Distribution of MTBDRplus assay results according to phenotypic drug resistance patterns using conventional drug
susceptibility testing for specimens with both valid culture and MTBDRplus assay results.
doi:10.1371/journal.pone.0031563.g002
Table 1. Performance parameters of MTBDRplus in detecting
INH R
‘, RIF R
‘, and MDR
‘ compared to conventional DST
(reference standard)
#.
Isoniazid Rifampicin Multidrug Resistance
Sensitivity 89.8 (84.4–93.9) 96.6 (91.4–99.1) 95.6 (90.1–98.6)
Specificity 99.3 (97.5–99.9) 98.8 (97.0–99.7) 98.5 (96.6–99.5)
PPV
* 98.8 (95.6–99.9) 96.6 (91.4–99.1) 95.6 (90.1–98.6)
NPV
* 93.3 (90.6–96.4) 98.8 (97.0–99.7) 98.5 (96.6–99.5)
#Values are percentages with 95% confidence interval in parentheses.
*PPV=positive predictive value, NPV=negative predictive value.
‘INH R=isoniazid resistance, RIF R=rifampin resistance, MDR=multidrug
resistance.
doi:10.1371/journal.pone.0031563.t001
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with previous reports [17,18]. In our study, the MTBDRplus assay
detected 97% of all RIF resistant cases with the most common
genetic mutations occurring in the 530–533 base pair region of
rpoB gene which also confirms two prior studies [7,15].
The use of rapid and accurate tests for drug resistance detection
offers hope in improving MDR-TB prevention and management
through the early initiation of appropriate therapy. While no
studies thus far have evaluated the clinical benefits of implement-
ing rapid diagnostics, the potential benefits can be inferred from
the drastic difference in time to results. Our study provides the
most detailed data to date on the comparison of time to results in a
real world setting and found that on average MDR-TB could be
detected 17 or 67 days earlier with the MTBDRplus assay as
compared to liquid and solid culture DST, respectively. When
available in low and middle-income countries, solid media is more
commonly used for AFB culture because of lower costs. The
impact of rapid detection of MDR-TB should be substantial given
that otherwise patients would have received more than two
months of an inappropriate treatment (i.e., first line regimen) that
could lead to further amplification of drug resistance prior to
detection of INH and/or RIF resistance [4,22,23]. Using existing
baseline DST data, an empiric MDR-TB regimen could be chosen
with a week of TB diagnosis thus helping prevent further
community and nosocomial spread of drug-resistant TB and
limiting disease progression. Specific mutations found by the
MTBDRplus assay may help in empiric choice of an anti-TB
treatment regimen. If mutations are detected in only the InhA gene
the isolate likely has low-level resistance to INH, and thus high
dose INH may have clinical effect. Additionally, ethionamide
inhibits InhA [24], and as our results demonstrate, if InhA
mutations are present ethionamide resistance is highly likely. In
Table 2. Average time to results in days for detection of TB and associated drug resistance (N=458)*.
Positive Solid Culture
Result Solid Media DST
‘
Positive Liquid Culture
Result Liquid Media DST
‘ MTBDRplus assay
All Cases 34.1 (11.3) 67.5 (15.0) 8.9 (3.9) 21.6 (9.3) 4.2 (1.8)
MDR TB 36.9 (13.4) 70.4 (19.2) 8.9 (4.9) 21.1 (8.1) 3.7 (1.7)
*Values are average number of days with one standard deviation in parentheses.
‘DST=drug susceptibility testing.
doi:10.1371/journal.pone.0031563.t002
Table 3. Pattern of genetic mutations in phenotypic drug-resistant Mycobacterium tuberculosis isolates using the Genotype
MTBDRplus assay.
Gene Band
Gene Region of
Mutation
IHN Mono Resistance*
,‘
n=63
RIF Mono Resistance*
,‘
n=2
MDR*
,‘
n=114
katG WT 315 34 (54) - 15 (10)
MUT1 S315T1 33 (52) - 105 (92)
MUT2 S315T2 0 - 3 (3)
inhA WT1 215/216 47 (75) - 85 (75)
WT2 28 62 (98) - 114 (100)
MUT1 C15T 17 (27) - 33 (30)
MUT2 A16G 0 - 1 (1)
MUT3A T8C 0 - 0
MUT3B T8A 0 - 0
rpoB WT1 506–509 - 2 (100) 114 (100)
WT2 510–513 - 2 (100) 114 (100)
WT3 513–517 - 2 (100) 106 (93)
WT4 516–519 - 2 (100) 106 (93)
WT5 518–522 - 2 (100) 114 (100)
WT6 521–525 - 2 (100) 112 (98)
WT7 526–529 - 2 (100) 108 (95)
WT8 530–533 - 0 22 (19)
MUT1 D516V - 0 7 (6)
MUT2A H526Y - 0 2 (2)
MUT2B H526B - 0 2 (2)
MUT3 S531L - 1 (50) 78 (68)
*Definitions of abbreviations: INH=isoniazid; RIF=rifampicin; MDR=multidrug-resistant.
‘Values are numbers, with percentages in parentheses.
doi:10.1371/journal.pone.0031563.t003
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[20] so that INH would not be clinically effective, ethionamide
could still be included in this scenario pending DST results.
Limitations of the MTBDRplus assay include detection of
resistance to only RIF and INH, and the need for high-level
technical skill and infrastructure usually relegating its use to a
referral or regional laboratory. However, we were able to bring
this technology to patients throughout the country of Georgia by
referring sputum specimens that were AFB smear positive at local
smear microscopy laboratories to the NRL. Continued surveil-
lance through traditional culture and DST methods will remain
important to individualize treatment regimens for drug-resistant
TB and in the detection of XDR-TB. To aid in rapid diagnosis of
XDR-TB, the Genotype MTBDRsl was recently developed to
detect resistance mutations to fluoroquinolones, aminoglycosides,
and ethambutol [25]. When used in combination with the
MTBDRplus assay, it may allow the detection of XDR-TB within
a week of TB diagnosis and could be triaged to be performed only
in cases when there was resistance to RIF or both INH and RIF.
The study was subject to a few limitations including only
enrolling patients with AFB smear-positive sputum specimens, not
having information on HIV status, and no methods in place for
identification of non-tuberculous mycobacterium (NTM). Based
on available evidence, the WHO currently recommends line probe
assays only in persons with an AFB smear-positive sputum [8].
Rates of HIV-TB co-infection in our cohort were likely low based
on a prior study, which found an HIV prevalence of 1.1% [26] in
tuberculosis patients in the Republic of Georgia. With no protocol
for NTM identification, we were unable to confirm the presence of
NTM in the six culture positive cases with a valid MTBDRplus
assay result but no binding to the MTBC probe.
In conclusion, we have demonstrated that the MTBDRplus
performed well in a ‘‘real world’’ situation at a NRL in a low and
middle-income country with a high-burdened TB including
MDR-TB. The line probe assay provided a much more rapid
diagnosis of drug resistant TB including MDR-TB compared to
convention laboratory tests (culture and DST). The line probe
assay and other molecular diagnostic tests have the potential to
significantly improve MDR-TB treatment, management and
prevention by providing rapid diagnosis and helping to ensure
patients are started on appropriate treatment regimens which will
not amplify resistance. Ongoing studies, including an evaluation of
this study cohort, are needed to help determine the impact on
patient and program outcomes and optimal use of rapid TB
diagnostic tests.
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